Pneumonitis Emerges as a Clinically Serious Toxicity in mRCC Immunotherapy
Immune checkpoint inhibitors have changed treatment expectations in metastatic renal cell carcinoma, but the lung does not always tolerate immune activation quietly. In a retrospective cohort from the University of Virginia Medical Center, immune checkpoint inhibitor-associated pneumonitis developed in 13 of 146 patients treated for metastatic renal cell carcinoma, an incidence of 8.9% with a 95% confidence interval of 4.8% to 14.7%.
The signal is clinically important because pneumonitis did not remain a mild, self-limited event in a meaningful fraction of patients. Five cases were grade 3 to 4 at diagnosis, and seven ultimately reached grade 3 or higher. Two patients died, both of whom had grade 1 to 2 pneumonitis when first identified. Low grade at presentation did not guarantee a benign course.
Prior Chest Radiation Stood Out as the Strongest Associated Factor
Treatment line and immunotherapy regimen did not significantly change the incidence of pneumonitis in this cohort. Prior chest radiation did.
Among patients with a history of chest radiation, pneumonitis occurred in 31.8% compared with 4.8% among those without prior chest radiation. The unadjusted odds ratio was 9.2, with a 95% confidence interval of 2.7 to 31.0, and the Benjamini-Hochberg-adjusted p value was 0.005. The study was not built to prove causation, but the magnitude of the association demands attention in routine practice.
Radiation may prime the lung in ways that make later immune activation more hazardous. Even when the tissue has visually recovered, prior radiation can leave behind fibrosis, vascular injury, altered antigen presentation, and a narrower physiologic reserve. When a checkpoint inhibitor releases inhibitory brakes on T-cell activity, the lung may be asked to absorb inflammation it can no longer buffer well. In this setting, a past radiation field may behave less like a historical footnote and more like a biologic sensitizer.
Diagnostic Review Relied on Multidisciplinary Confirmation
The study design used more than chart review alone to define cases. Adults with mRCC who began first- or second-line ICI therapy between 2015 and 2023 were evaluated retrospectively, and potential pneumonitis cases underwent multidisciplinary clinical review. Two thoracic radiologists independently reviewed the available computed tomography scans.
That layered approach matters because pneumonitis in the setting of cancer therapy is a diagnosis that can be blurred by infection, tumor progression, prior radiation change, pulmonary edema, and other drug toxicities. Independent imaging review strengthens case identification, while multidisciplinary assessment reduces the chance that all ground-glass change gets flattened into a single label. The cohort still remains small, and the work is exploratory, but the diagnostic process was deliberately careful.
Severity Often Required Steroids, Yet Not Every Patient Recovered
Nine patients, or 69%, received high-dose systemic corticosteroids. Eleven patients, or 85%, improved or resolved with initial management. Five patients later underwent ICI rechallenge after clinical recovery, and none experienced recurrent pneumonitis.
The response pattern suggests that prompt recognition can still reverse many cases, particularly when immunosuppression is started early. High-dose corticosteroids remain the backbone of management because the biology is fundamentally inflammatory: activated immune cells infiltrate the lung parenchyma, alveolar-capillary gas exchange worsens, and symptoms can progress faster than imaging findings appear to stabilize. In patients who recover, the inflammatory cascade can sometimes be pulled back before lasting damage develops.
Still, the deaths remind clinicians that improvement is not guaranteed, and initial grade does not always predict the eventual trajectory. The two fatal cases began as grade 1 to 2 pneumonitis, then worsened. In practical terms, even modest symptoms after ICI exposure deserve active follow-up, repeat assessment, and a low threshold for escalation if oxygenation or radiographic findings change.
Pneumonitis was not rare, and it was not always forgiving.
Rechallenge After Recovery May Be Feasible in Selected Patients
Five patients were rechallenged with immunotherapy after clinical recovery, and none developed recurrent pneumonitis during rechallenge. That finding is encouraging, but it should be read as a small, selected experience rather than a universal rule.
Rechallenge decisions in mRCC often hinge on the balance between oncologic benefit and the risk of recurrent lung injury. The absence of recurrence in this subset suggests that carefully chosen patients can sometimes resume treatment safely after recovery, especially when the initial event resolves fully and surveillance is close. Even so, the number is too small to establish a durable safety estimate, and the follow-up context is not enough to justify broad reassurance.
What This Cohort Adds to Routine Care
For oncologists treating mRCC, the practical message is direct: prior chest radiation should heighten vigilance before and during ICI therapy. The association seen here is hypothesis-generating rather than definitive, but it is strong enough to influence bedside questioning, imaging review, and symptom monitoring.
Baseline respiratory symptoms, prior thoracic radiation fields, and any new cough or dyspnea during treatment should be taken seriously. In a disease where immune checkpoint inhibitors can extend survival, the cost of missing early pneumonitis is high, especially because grade 1 to 2 disease can still deteriorate into severe or fatal illness. The study also supports continued use of corticosteroids for clinically significant cases and a cautious, individualized approach to rechallenge after recovery.
The evidence remains limited by retrospective design, the small number of events, and the lack of detailed radiation dosimetry or broader confounder data. Larger studies with more granular radiation exposure information will be needed to determine whether prior chest radiation independently raises pneumonitis risk or simply marks a group with more fragile lungs and more complex treatment histories. Until then, the safest reading is straightforward: in mRCC, checkpoint blockade can injure the lung, prior chest radiation may magnify that danger, and early-grade disease should never be dismissed as trivial.